Saturday, September 22, 2018 8:41:19 AM
The date of this prospectus supplement is September 21, 2018.
Settlement Agreement
On September 8, 2018, we entered into a Confidential Settlement Agreement and Release, or the Settlement Agreement, with Multicell Immunotherapeutics, Inc., or Multicell, to settle a breach of contract lawsuit. As part of the Settlement Agreement, we agreed to issue to Multicell 75,000 shares of Common Stock at an agreed value of $2.00 per share. Multicell is a selling stockholder. For purposes of the table below, beneficial ownership is based on the securities held of record by the selling stockholders as of May 11, 2018.
https://ir.gtbiopharma.com/all-sec-filings/content/0001654954-18-010380/0001654954-18-010380.pdf
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM